ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Opsens Inc (QX)

Opsens Inc (QX) (OPSSF)

2.1389
0.00
(0.00%)
Closed July 26 4:00PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
2.1389
Bid
2.12
Ask
2.35
Volume
-
0.00 Day's Range 0.00
1.18 52 Week Range 2.14
Previous Close
2.1389
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
-
Financial Volume
-
VWAP
-

OPSSF Latest News

No news to show yet.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520.6889347.51241379311.452.141.18655232.03079557CS
1560.3437319.14717023171.79522.990.97449011.90432672CS
2601.40113189.9064787210.73782.990.2945387941.70413376CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WINTWindtree Therapeutics Inc
$ 8.24
(150.46%)
48.57M
BFIBurgerFi International Inc
$ 0.4206
(97.37%)
313.59M
NBSTWNewbury Street Acquisition Corporation
$ 0.1349
(92.71%)
122.1k
YIBOPlanet Image International Ltd
$ 2.915
(53.43%)
259.77k
CREVCarbon Revolution Public Ltd
$ 9.00
(45.87%)
8.06M
NMHINatures Miracle Holding Inc
$ 0.2035
(-48.06%)
7.69M
TANHTantech Holdings Ltd
$ 0.2585
(-47.23%)
6.75M
DXCMDexCom Inc
$ 64.00
(-40.66%)
53.92M
PSIGPS International Group Ltd
$ 1.42
(-31.40%)
716.26k
POAIPredictive Oncology Inc
$ 1.36
(-27.27%)
6.02M
SLNASelina Hospitality PLC
$ 0.0305
(-18.88%)
408.45M
BFIBurgerFi International Inc
$ 0.4206
(97.37%)
313.59M
NVDANVIDIA Corporation
$ 113.06
(0.69%)
293.33M
SQQQProShares UltraPro Short QQQ
$ 9.10
(-2.88%)
176.49M
SGMOSangamo Therapeutics Inc
$ 0.8612
(28.15%)
123.71M

OPSSF Discussion

View Posts
Renee Renee 7 months ago
OPSSF: effective Dec. 14,2023: 9500-7704 Quebec Inc., a wholly-owned subsidiary of Haemonetics Corporation, acquired all of the issued and outstanding Common Shares of the Company pursuant to a plan of arrangement. Shareholders of the Company will receive $2.90 in cash, without interest, for each Common Share held.

FINRA will delete the symbol:

https://otce.finra.org/otce/dailyList?viewType=Deletions
👍️0
MasterChi MasterChi 7 years ago
Opsens Reports Q1 2018 Results - Record Quarterly Revenues With Growth in all Geographic Regions
Jan 15, 2018

OTC Disclosure & News Service

-
Opsens Reports Q1 2018 Results - Record Quarterly Revenues With Growth in all Geographic Regions

Canada NewsWire

QUEBEC CITY, Jan. 15, 2018

QUEBEC CITY, Jan. 15, 2018 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (TSX: OPS) (OTCQX: OPSSF) today reported its results for the first quarter ended November 30, 2017.

Highlights

Consolidated revenues reached $6,364,000 for Q1 2018 compared with $3,745,000 for the same period last year, an increase of $2,619,000 or 70%;
Fractional Flow Reserve ("FFR") revenues for the first quarter of fiscal 2018 amounted to $3,359,000 compared with $2,743,000 for the same period last year, an increase of $616,000 or 22%;
Other medical revenues in the quarter reached $1,352,000 compared with $496,000 for the same period last year, an increase of $856,000 or 173%;
Conversion of the US$2,000,000 convertible debenture into common shares of the Company. As at November 30, 2017, Opsens had a cash position of $13.4 million ($12.6 million as at August 31, 2017).

Execution of the growth strategy

FFR revenues grew in all key markets in the first quarter of 2018. "We are convinced that the OptoWire's distinctive features, widely recognized by industry key opinion leaders in the field of interventional cardiology, will enable us to capitalize on the fast-growing FFR market," said Louis Laflamme, President and CEO of Opsens.

"We continue to focus on improving sales, production and innovation to capitalize on the FFR market," added Mr. Laflamme.

Financial results - quarter ended November 30, 2017

Opsens' product sales reached $5,336,000 for the three-month period ended November 30, 2017, compared with $3,654,000 for the corresponding period the previous year. This significant increase is mainly explained by an increase in FFR income, other medical income and in industrial income compared with the corresponding quarter in 2016. Also, the Company recognized a non-recurring licensing revenues of $1,028,000 for a total consolidated revenues of $6,364,000.

Gross margin increased to $3,336,000 for the quarter ended November 30, 2017 compared with $1,191,000 for the same period a year earlier. An amount of $937,000 of this increase was driven by the non-recurring licensing revenues.

The net loss amounted to $936,000 for the three-month period ended November 30, 2017, compared with a net loss of $2,541,000 for the corresponding period last year. The change in the fair value of the debenture converted into shares during the quarter resulted in a non-cash charge of $501,000 during the quarter ended November 30, 2017.




https://www.otcmarkets.com/stock/OPSSF/news/Opsens-Reports-Q1-2018-Results---Record-Quarterly-Revenues-With-Growth-in-all-Geographic-Regions?id=180365&b=y
👍️0
MasterChi MasterChi 7 years ago
OPSENS REPORTS Q1 2018 RESULTS – RECORD QUARTERLY REVENUES WITH GROWTH IN ALL GEOGRAPHIC REGIONS

https://www.otcmarkets.com/stock/OPSSF/news/OPSENS-REPORTS-Q1-2018-RESULTS-%E2%80%93-RECORD-QUARTERLY-REVENUES-WITH-GROWTH-IN-ALL-GEOGRAPHIC-REGIONS?id=180565&b=y
👍️0

Your Recent History

Delayed Upgrade Clock